DFTX
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. (DFTX) has 16 SEC Form 4 filings (16 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Jun 26, 2026.
Insiders have net sold $2.6M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Robert Barrow
- Employees:74
- HQ:New York, NY, US
- IPO:2016-11-15
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.6M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Market Cap
$4.7B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Wiley Matthew T.First filing | Chief Commercial Officer | Sale | 2,867 | $129K | Jun 26 | SEC ↗ |
Barrow RobertFirst filing | Chief Executive Officer | Sale | 29,208 | $1.3M | Jun 26 | SEC ↗ |
Sullivan MarkFirst filing | Chief Legal Officer | Sale | 13,008 | $586K | Jun 26 | SEC ↗ |
Karlin DanielFirst filing | Chief Medical Officer | Sale | 10,035 | $452K | Jun 26 | SEC ↗ |
Roberts BrandiFirst filing | Chief Financial Officer | Sale | 3,013 | $136K | Jun 26 | SEC ↗ |
Related companies
Definium Therapeutics, Inc. is in the Healthcare sector.